PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteCasgevy became the first therapy using CRISPR/Cas9 to receive U.S. Food and Drug Administration approval. It is a patient-specific treatment for sickle cell disease: a person’s blood-forming stem cells are collected, edited outside the body to increase fetal hemoglobin, and returned after high-dose chemotherapy. The milestone is real, but this is an intensive transplant-like treatment—not a simple injection or a guarantee of lifelong freedom from disease.
What “the first gene-editing treatment” means
Casgevy, also called exagamglogene autotemcel or exa-cel, was the first FDA-approved therapy to use CRISPR/Cas9 genome editing. The FDA announced its approval on December 8, 2023, for people aged 12 and older with sickle cell disease and recurrent vaso-occlusive crises. The milestone is specifically about FDA approval of a CRISPR/Cas9-based therapy; it does not mean gene editing or gene therapy had never been used before.
As an Amazon Associate I earn from qualifying purchases.
Casgevy is a cell therapy made for an individual patient. It does not edit genes directly inside the person’s body: clinicians collect the patient’s own blood-forming stem cells, modify them in a laboratory, and later infuse them back.
How Casgevy works
Sickle cell disease is inherited. Abnormal hemoglobin can make red blood cells rigid and sickle-shaped. Those cells may obstruct blood flow, causing painful vaso-occlusive crises and contributing to organ damage.
#1 Best Overall
Casgevy uses CRISPR/Cas9 to edit a patient’s blood-forming stem cells so they produce more fetal hemoglobin. Fetal hemoglobin can reduce red-cell sickling. The edited cells are intended to take hold in the bone marrow and make blood cells that contain increased fetal hemoglobin.
What treatment involves
Although Casgevy is given as a single infusion, getting to that infusion involves several stages. The FDA and European Medicines Agency describe a process that includes collecting the patient’s cells, editing them, giving high-dose conditioning chemotherapy, and reinfusing the modified cells. The chemotherapy clears space in the bone marrow for the edited cells to engraft. This is a demanding clinical process, not a one-visit injection.
- Cell collection: The patient’s blood-forming stem cells are collected for manufacturing.
- Editing: CRISPR/Cas9 is used to modify those cells to increase fetal hemoglobin.
- Conditioning: High-dose chemotherapy clears bone-marrow cells before the edited cells are returned.
- Reinfusion and follow-up: The modified cells are infused, and the patient receives specialist care and monitoring.
Who is eligible, and where?
Approval depends on the regulator and the condition. In the United States, the FDA approval announced in 2023 covers sickle cell disease in patients aged 12 or older who have recurrent vaso-occlusive crises. That indication does not mean every person who meets the age and diagnosis description is automatically suitable for treatment; individual decisions require specialist assessment.
In the European Union, the EMA lists conditional marketing authorisation, valid from February 9, 2024, for eligible patients aged 12 or older with sickle cell disease or transfusion-dependent beta-thalassaemia. In beta-thalassaemia, patients do not make enough hemoglobin and may need regular transfusions. The EU indication therefore includes a second condition that is not part of the U.S. FDA approval described here.
The EMA’s authorisation is conditional, meaning additional evidence is required and the available information is reviewed as it accumulates.
What the clinical results show
The studies report encouraging outcomes over defined periods, but they were ongoing and were not head-to-head comparisons against another medicine or placebo.
| Evidence | Reported result | Important context |
|---|---|---|
| FDA, 2023: sickle cell disease | 29 of 31 evaluable participants (93.5%) had no severe vaso-occlusive episodes for at least 12 consecutive months. | This was an ongoing, single-arm trial; the reported period was within 24 months of follow-up. |
| EMA, 2024: sickle cell disease | 28 of 29 patients had no painful crises for at least 12 consecutive months after treatment; none of the 29 was hospitalised for painful crises over that interval. | The EMA described the study results as interim and ongoing. |
| EMA, 2024: transfusion-dependent beta-thalassaemia | 39 of 42 patients maintained haemoglobin above 9 g/dL without transfusions for at least 12 consecutive months. | The EMA described the study results as interim and ongoing. |
These figures describe outcomes in particular study participants over stated follow-up periods. They do not predict an individual patient’s result or establish lifelong durability. The FDA says treated patients will be followed in a long-term study.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Is Casgevy a cure for sickle cell disease?
It is more accurate to describe Casgevy as a potentially disease-modifying treatment than to promise a cure. The trial results show that many participants reached extended periods without severe crises, but they do not establish that every recipient will be free of symptoms, complications, or future treatment needs for life. How long benefits last and what long-term effects may emerge require continued follow-up.
Best Value
Risks and side effects
Casgevy involves high-dose chemotherapy and stem-cell transplantation, and many reported effects are associated with the conditioning treatment. The FDA lists low platelet and white blood cell counts, mouth sores, nausea, musculoskeletal and abdominal pain, vomiting, febrile neutropenia, headache, and itching among common side effects. The EMA also identifies headache, nausea, and muscle and bone pain as common effects.
The EMA notes a theoretical cancer risk from unintended genetic changes. No such cases had been seen in the evidence cited in its overview, but that does not settle the question of long-term risk. It also notes a potential bleeding risk associated with low platelet counts. The EMA describes a 15-year registry-based study for monitoring potential risks.
How Casgevy differs from Lyfgenia
Lyfgenia is another FDA-approved cell-based gene therapy for sickle cell disease, but it uses a different genetic modification approach. The FDA says Lyfgenia uses a lentiviral vector to modify cells so they produce a gene-therapy-derived hemoglobin; Casgevy uses CRISPR/Cas9 editing to increase fetal hemoglobin.
| Comparison | Casgevy | Lyfgenia |
|---|---|---|
| Modification approach | CRISPR/Cas9 editing to increase fetal hemoglobin (FDA). | Lentiviral vector used to modify cells to produce a gene-therapy-derived hemoglobin (FDA). |
| FDA status in the cited announcement | FDA-approved for sickle cell disease in patients aged 12 or older with recurrent vaso-occlusive crises. | FDA-approved cell-based gene therapy for sickle cell disease; the exact eligibility wording is not stated in the FDA comparison information cited here. |
| Outcome figures and follow-up | The FDA reported 29 of 31 evaluable participants (93.5%) without severe vaso-occlusive episodes for at least 12 consecutive months during 24-month follow-up in an ongoing single-arm trial. | Not stated in the FDA comparison information cited here. |
| Specific safety warning noted by FDA | The Lyfgenia boxed warning should not be attributed to Casgevy. | The FDA reports blood cancer in patients treated with Lyfgenia and requires lifelong monitoring through a boxed warning. |
The Lyfgenia warning is specific to that product in the FDA information; it is not a Casgevy warning.
What is known about cost and access
The official information described here establishes regulatory indications and treatment processes, but it does not establish current cost, insurance coverage, or availability by country. Access should be checked with a qualified treatment center and the relevant health system rather than inferred from an older price estimate or a past availability description.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
